Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab Out-Licenses Bi-Specific to South Korea's ABL Bio in $100 Million Deal

publication date: Jul 26, 2018

I-Mab Biopharma of Shanghai out-licensed global rights (ex-China) for bispecific antibodies to ABL Bio of South Korea in an agreement worth about $100 million. Neither the target nor the proposed indications of the molecules were disclosed. I-Mab is focused on biologics for immuno-oncology and immuno-inflammation needs. ABL will make a $2.5 million payment to I-Mab up front and agreed to pay around $100 million in milestones, plus royalties. The two companies also agreed to co-develop three additional BsAbs globally as part of the partnership. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital